Risk factors
Maxcyte (MXCT) risk factors
Item 1A of every Maxcyte, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors67 risks7 new9 dropped9 reworded
MaxCyte faces Nasdaq delisting risks due to low share prices, supply chain disruptions, and tariff uncertainties in international trade.
Filed Mar 25, 2026 - FY2024 10-K risk factors69 risks
MaxCyte faces heavy risks from reliance on biotech customers, customer clinical setbacks, and manufacturing scale-up challenges for its ExPERT platform.
Filed Mar 11, 2025